Kadcyla: Medicine to treat breast cancer

2021-06-17 02:48 PM

Initiate infusion over 90 minutes, monitor patient, during infusion and for at least 90 minutes after infusion. If it is well tolerated, subsequent doses can be infused within 30 minutes

Producer

Roche.

Ingredient

Trastuzumab emtansine.

Indications/Uses

HER2-positive tumor, metastatic breast cancer, or inoperable locally advanced breast cancer, previously treated with trastuzumab and a taxane.

Dosage/Instructions for use

21-day course: 3.6 mg/kg every 3 weeks until disease progression or unacceptable toxicity occurs. Initiate infusion over 90 minutes, monitor patient during infusion and for at least 90 minutes after infusion; if well tolerated: subsequent doses may be infused within 30 minutes, monitoring the patient during the infusion and at least 30 minutes after the infusion. Management of adverse events may require temporary discontinuation, dose reduction (dosage should not be gradually increased after dose reduction) or discontinuation of therapy.

How to use

Slow intravenous infusion.

Contraindications

Hypersensitivity to the drug components.

Caution

Patients with liver failure. Children < 18 years: Safety and efficacy have not been established. Pregnant women: not recommended, close monitoring if treated; Stop breastfeeding before starting treatment. Withhold treatment if grade 3-4 peripheral neuropathy is present until symptoms disappear or symptoms improve below grade 2. Permanently discontinue treatment if diagnosed with interstitial lung disease or inflammation pulmonary transaminases, serum transaminases, and total bilirubin >3 times and >2 times the upper limit of normal, respectively, biopsies confirmed nodular regenerative liver hyperplasia, and life-threatening fluid-related events network.

Side Effects

Very common: thrombocytopenia, anemia; nausea, constipation, vomiting, diarrhea, dry mouth, abdominal pain, stomatitis; fatigue, fever, weakness, chills; Urinary tract infections; increased transaminases; hypokalemia; musculoskeletal pain, arthralgia, myalgia; headache, peripheral neuropathy; insomnia; nosebleeds, cough, trouble breathing; rash; hemorrhage. Common: neutropenia; left ventricular dysfunction; dry eyes, increased lacrimation, blurred vision, conjunctivitis; undigested; peripheral edema; hypersensitivity; infusion-related reactions; increased serum alkaline phosphatase; dizziness, taste disturbances; itching; hypertension.

Interactive

Use with caution strong CYP3A inhibitors.

Classification (US)/Pregnancy

Grade D: There is evidence of a risk in the human fetus, but because of the benefits, the use of the drug during pregnancy can be approved, regardless of the risk (e.g., the need for drug use during pregnancy). a life-threatening situation or in a serious illness where safe drugs cannot be used or are ineffective).

Targeted Cancer Therapy [Targeted Cancer Therapy]

Presentation/Packaging

Kadcyla Powder for infusion 100 mg.

Kadcyla Powder for infusion 160 mg.